(Q38977579)

English

A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.

scientific article

In more languages
default for all languages
No label defined

No description defined

Statements

A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit